Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
After achieving optimal results, many patients transition to a maintenance protocol with less frequent dosing
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Long-term prescribing
The rotarod test was employed to assess motor endurance and pain function
This has several important implications for manufacturers: Early launch benchmarks may understate success if they focus primarily on switching behavior rather than new-to-therapy initiation The addressable market for oral GLP-1s may be larger than previously modeled , particularly if similar barriers exist across obesity and cardiometabolic indications Pipeline assets following oral semaglutide may enter a more receptive market , where the viability of oral administration has already been established What Great Looks Like: Speed and Clinical Depth at Launch Imagine if, within weeks of launch, pharma leaders could understand the earliest signals of launch performanceincluding prescription activity, patient flow, site of care, and early access dynamicsby assessing near-real-time, large-scale claims and EMR data
